← Back

Candel Therapeutics Inc

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops immunotherapies for cancer patients. Its pipeline includes CAN-2409, in Phase 2a trials for prostate cancer and non-small cell lung cancer (NSCLC), and CAN-3110, in Phase Ib trials for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus-based platform that leverages human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. Formerly known as Advantagene, Inc., it changed its name to Candel Therapeutics, Inc. in November 2020, was incorporated in 2003, and is headquartered in Needham, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving CADL
United States
CADL▼

Candel Therapeutics Q2 GAAP EPS misses by $0.29

Candel Therapeutics reported a second-quarter GAAP loss of $0.52 per share, missing analyst expectations by $0.29. The company held cash and cash equivalents of $201.6 million as of June 30, 2026, which it expects will fund operations into the first quarter of 2028. That runway includes activities to support the potential commercial launch of aglatimagene in 2027.
CADL ▼
CADL · Capital · Negative Q2 GAAP EPS missed by $0.29, indicating weaker-than-expected financial performance.
Read original ↗
Seeking Alpha·53dRead more →
CADL2

Candel Therapeutics Grants Inducement Stock Options to New Chief Commercial Officer

Candel Therapeutics granted inducement stock options to newly appointed Chief Commercial Officer Mark Sims. The options allow the purchase of 285,000 shares of common stock at an exercise price of $10.03 per share, matching the July 6, 2026 closing price on Nasdaq. The award vests 25% on the first anniversary of Mr. Sims' start date, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on his continued service. The grant was made under the company's 2025 Inducement Plan as an employment inducement in accordance with Nasdaq Listing Rule 5635(c)(4).
CADL
CADL · Capital · Neutral Grant of inducement stock options to new CCO; aligns incentives but dilutive; no direct business impact.
Read original ↗
GlobeNewswire·88dRead more →
CADL▲

Five Biotech Stocks Surge 105% to 235% to New Highs

Five biotech stocks profiled by RTTNews reached new 52-week highs last week, with gains ranging from 105% to 235% since their respective publication dates. Twist Bioscience soared 235% to a high of $104.23, driven by strong revenue and an upcoming quarterly report. Biodesix climbed 124% to $23.34 following better-than-expected results, raised guidance, and positive clinical validation data. Mirum Pharmaceuticals rose 133% to $124.44 on consistent revenue growth, the Bluejay Therapeutics acquisition, and positive trial results for Brelovitug and Volixibat. Candel Therapeutics advanced 108% to $9.99 after extended survival data for Aglatimagene and a commercialization agreement with EVERSANA. Indivior Pharmaceuticals gained 105% to $42.81, supported by solid earnings, upbeat guidance, and real-world evidence favoring Sublocade.
BDSX ▲CADL ▲INDV ▲MIRM ▲TWST ▲
BDSX · Capital · Positive Better-than-expected results, raised guidance, and positive clinical validation data drove stock to new high.
CADL · Technology · Positive Extended survival data for Aglatimagene and a commercialization agreement with EVERSANA drove stock higher.
INDV · Capital · Positive Solid earnings, upbeat guidance, and real-world evidence favoring Sublocade supported stock.
MIRM · Capital · Positive Consistent revenue growth, Bluejay Therapeutics acquisition, and positive trial results for Brelovitug and Volixibat drove stock.
TWST · Capital · Positive Strong revenue and upcoming quarterly report drove stock to new high.
Read original ↗
RTTNews·98dRead more →
CADL▲

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026. He will lead commercial strategy and launch readiness for the Biologics License Application submission planned for the fourth quarter of 2026 and the estimated 2027 launch of aglatimagene besadenovec, the company's localized prostate cancer treatment. Sims previously served at AstraZeneca as Vice President and Global Franchise Head, directing commercial strategy for one of its largest business franchises. President and CEO Paul Peter Tak noted that intermediate- to high-risk localized prostate cancer represents a large market opportunity, with approximately 65,000 patients diagnosed annually in the United States who are candidates for radiotherapy-based treatment. Sims brings over 25 years of experience from roles at AstraZeneca, Novartis Idenix Pharmaceuticals, and Merck & Co.
CADL ▲
CADL · Capital · Positive Appointment of experienced CCO to lead commercial strategy for upcoming BLA submission and launch of prostate cancer treatment.
Read original ↗
ExecEdge·101dRead more →
© 2026 MarketDXAsset